CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
Benoit YouVasudha SehgalBalakrishna HosmaneXin HuangPeter J AnsellMinh H DinhKatherine Bell-McGuinnXizhi LuoGini F FlemingMichael L FriedlanderMichael A BookmanKathleen M MooreKarina Dahl SteffensenRobert L ColemanElizabeth M SwisherPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
status, the tumor primary chemosensitivity observed during the first-line chemotherapy might be another complementary determinant of poly (adenosine diphosphate-ribose) polymerase inhibitor efficacy.